Literature DB >> 30992515

Cause, Consequence or confounding? The kidney in hypertension.

Marcel Ruzicka1,2, Swapnil Hiremath3,4.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 30992515     DOI: 10.1038/s41371-019-0199-6

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


× No keyword cloud information.
  13 in total

1.  Association of Adolescent Hypertension With Future End-stage Renal Disease.

Authors:  Adi Leiba; Boris Fishman; Gilad Twig; David Gilad; Estela Derazne; Ari Shamiss; Tamar Shohat; Ofir Ron; Ehud Grossman
Journal:  JAMA Intern Med       Date:  2019-04-01       Impact factor: 21.873

2.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

Review 3.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Authors:  Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi
Journal:  Lancet       Date:  2015-12-24       Impact factor: 79.321

4.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

6.  Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease.

Authors:  Chi-yuan Hsu; Charles E McCulloch; Jeanne Darbinian; Alan S Go; Carlos Iribarren
Journal:  Arch Intern Med       Date:  2005-04-25

7.  Hypertension as cause and consequence of renal disease in the 19th century.

Authors:  J Harlos; A Heidland
Journal:  Am J Nephrol       Date:  1994       Impact factor: 3.754

8.  Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva
Journal:  N Engl J Med       Date:  2017-11-04       Impact factor: 91.245

9.  Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.

Authors:  Rakesh Malhotra; Timothy Craven; Walter T Ambrosius; Anthony A Killeen; William E Haley; Alfred K Cheung; Michel Chonchol; Mark Sarnak; Chirag R Parikh; Michael G Shlipak; Joachim H Ix
Journal:  Am J Kidney Dis       Date:  2018-10-02       Impact factor: 8.860

10.  Usefulness of the blood pressure classification in the new 2017 ACC/AHA hypertension guidelines for the prediction of new-onset chronic kidney disease.

Authors:  Toshiki Maeda; Chikara Yoshimura; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Yasuhiro Abe; Kousuke Masutani; Hitoshi Nakashima; Shigeaki Mukoubara; Hisatomi Arima
Journal:  J Hum Hypertens       Date:  2019-04-16       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.